基于生理药代动力学模型探讨巴瑞替尼与托法替布在老年COVID-19患者中的给药建议
该研究采用年龄依赖性生理药代动力学(PBPK)建模框架,评估巴瑞替尼与托法替布在White与中国老年COVID-19合并慢性肾功能不全患者中的现行给药策略。文献来源的PBPK药物模型经先验证后,用代表不同年龄组、种族和肾功能损害分期的人群模型进行前瞻性模拟。结果显示,两药因肾功能不全导致的全身暴露升高在老年人群比一般White人群更明显,但现行基于肾功能的剂量调整总体充分;例外是White轻度肾损老年受试者,现行4 mg巴瑞替尼推荐使全身暴露升高2.31倍,减至2 mg可将潜在风险降至可接受的1.15倍。中国人群中两药全身暴露与肾功能不全的关系相似。作者结论认为,PBPK建模支持在不同年龄组和肾功能成人患者中合理审慎地调整这两种COVID-19治疗药物的剂量。
要点
- White轻度肾损老年患者现行4 mg巴瑞替尼使全身暴露升高2.31倍,减至2 mg可降至可接受的1.15倍。
- 两药因肾功能不全导致的全身暴露升高在老年人群比一般White人群更明显。
- 尽管如此,模拟证实两药现行基于肾功能的剂量调整总体充分。
- 中国人群中两药全身暴露与肾功能不全的关系与White人群相似。
- 美国NIH推荐巴瑞替尼与托法替布作为COVID-19免疫调节药物,FDA对巴瑞替尼授予紧急使用授权,但说明书仅提供成人剂量信息。
适用人群与场景
- White与中国老年COVID-19合并慢性肾功能不全患者
- 研究模拟覆盖不同年龄组、种族和肾功能损害分期的人群
- 两药为美国NIH推荐的COVID-19免疫调节药物,巴瑞替尼获FDA紧急使用授权,但说明书仅提供成人剂量信息
处置流程与药物剂量
- White轻度肾损老年患者:现行推荐巴瑞替尼4 mg使全身暴露升高2.31倍,减至2 mg可将潜在风险降至可接受的1.15倍
- 两药现行基于肾功能的剂量调整总体充分
研究设计与关键结果
- 采用年龄依赖性PBPK建模框架,文献来源的PBPK药物模型先经验证,再用代表不同年龄组、种族和肾功能损害分期的人群模型进行前瞻性模拟。
- 肾功能不全导致两药全身暴露升高,在老年人群比一般White人群更明显。
- White轻度肾损老年受试者现行4 mg巴瑞替尼使全身暴露升高2.31倍,减至2 mg可降至1.15倍。
- 中国人群中两药全身暴露与肾功能不全的关系相似。
证据类型、等级与局限
- 证据类型:基于PBPK建模的模拟研究(前瞻性模拟)
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为,PBPK建模支持在不同年龄组和肾功能成人患者中合理审慎地调整巴瑞替尼与托法替布的剂量。
- White轻度肾损老年患者使用巴瑞替尼时,作者模拟提示4 mg暴露升高2.31倍、2 mg可降至1.15倍。
指南或共识出处
- 美国NIH推荐巴瑞替尼与托法替布作为COVID-19免疫调节药物
- 美国FDA对巴瑞替尼授予紧急使用授权
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Janus kinase (JAK) inhibitors baricitinib and tofacitinib are recommended by the US National Institutes of Health as immunomodulatory drugs for coronavirus disease 2019 (COVID-19) treatment. In addition, baricitinib has recently received Emergency Use Authorization from the US Food and Drug Administration, although the instruction provided dosing information only for adults. Geriatrics with organ dysfunction are one of the most vulnerable cohorts when combating the pandemic. The aim of the present work was to evaluate current dosing strategies of baricitinib and tofacitinib for potential COVID-19 treatment for White and Chinese geriatric patients with chronic renal impairment. An established physiologically-based pharmacokinetic (PBPK) modeling framework for age-dependent simulations was utilized. PBPK drug models adopted from literature were first verified. Several population models representing different age groups, ethnicities, and stages of renal impairment were used for prospective simulations. Notwithstanding the increase in systemic exposure of both drugs resulting from renal dysfunction was more pronounced for geriatrics than general White populations, our simulations confirmed their current dosage adjustments based on renal functions are broadly adequate. The exception being White older subjects with mild renal impairment where current recommendation of 4 mg baricitinib yielded a 2.31-fold increase in systemic exposure, and reduction to 2 mg could mitigate the potential risk to an acceptable 1.15-fold. Comparable relationships between systemic exposure and renal dysfunction were observed for both drugs in the Chinese population. In summary, PBPK modeling of both JAK inhibitors supports the rational and prudent dose adjustments of these COVID-19 therapeutics among adult patients of different age groups and renal functions.
参考来源
- Wang Z, Chan ECY. Physiologically-Based Pharmacokinetic Modelling to Investigate Baricitinib and Tofacitinib Dosing Recommendations for COVID-19 in Geriatrics. Clin Pharmacol Ther. 2022. PMID: 35380176. doi:10.1002/cpt.2600
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。